Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

285.31 +1.91 (+0.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Masters In Trading - Saturday, June 22
In this video, I discuss a stock that is expected to see major upside, and I take a closer look at my portfolio. 
Via Talk Markets
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today
Via Benzinga
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Behind the Scenes of Alnylam Pharmaceuticals's Latest Options Trends
Via Benzinga
(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest
Via Benzinga
How Is The Market Feeling About Alnylam Pharmaceuticals?
Via Benzinga
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Alnylam Issues 2023 Corporate Responsibility Report
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
ALNY Stock Earnings: Alnylam Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
ALNY stock results show that Alnylam Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data
The latest findings from Alnylam Pharmaceuticals' KARDIA-2 Phase 2 study are on zilebesiran's efficacy and safety in treating hypertension. Results show significant reductions in systolic blood... 
Via Benzinga
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting. 
Via Investor's Business Daily
Exposures Product Safety
3 Biotech Stocks to Buy on the Dip: March 2024
Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three. 
Via InvestorPlace
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years
Via Benzinga
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses. 
Via InvestorPlace
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates
This week, data from Novo Nordisk’s early-stage study on a new weight loss pill called amycretin showed that it could be more effective than Wegovy. Meanwhile, the FDA approved Johnson & Johnson's lung... 
Via Talk Markets
Exposures Product Safety
Roche/Alnylam Blood Pressure Drug Aces In Mid-Stage Trial, Analyst Says Zilebesiran As Promising Opportunity In Addressing Global Hypertension Challenges
Alnylam's KARDIA-2 Phase 2 study on zilebesiran, an RNAi therapeutic for hypertension. Clinically significant reductions in blood pressure observed, with optimistic outlook on upcoming ACC event. 
Via Benzinga
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today
Via Benzinga
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback